New Delhi: India will be able to receive Russian Coronavirus Vaccine by November. Dr. Reddy’s Lab has tied up with Russian manufacturer Russian Direct Investment Fund (RDIF) to sell 10 million vaccines of Corona in India.
According to reports, RDIF has launched Sputnik V vaccine in Russia for clinical trials and distribution in India. Reddy’s Laboratories is in agreement with RDIF. As per the agreement Russian company in India Will supply 100 million vaccines to Reddy’s. After the agreement, Dr. Reddy’s stock on BSE reached 4624.45 with strength of Rs 181.
RDIF CEO Kirill Dimitriv said in a statement that the vaccine will be available in India by November if the trial is successful. Dr. Reddy’s has a business presence in Russia for almost 25 years and is a major Indian company.
He claimed that the Russian vaccine based on the Human Adenovirus Dual Vector platform would help fight COVID-19 in India. ‘250 clinical trials of human adenovirus dual vector platform have been done in Russia and no possible negative results have been seen so far’, further added.
Dr. GV Prasad, managing director of Reddy’s said, ‘Phase 1 and Phase 2 testing of this vaccine have been successful and now we will test its third phase in India, so that the necessary regulatory conditions are met.